Relationship of TP53 and Ki67 expression in bladder cancer under WHO 2004 classification

Journal of B.U.ON.

Volumn 18, Issue 2, 2013, Pages 420-424

  Wang, Lujia ^a   Feng, Chenchen ^a   Ding, Guanxiong ^a   Zhou, Zhongwen ^a   Jiang, Haowen ^a   Wu, Zhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Esophageal carcinoma; Meta analysis; Prognostic factor; Vascular endothelial growth factor

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TERMINOLOGY AS TOPIC; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84879588874     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66:4-34. (Pubitemid 43049607)
2. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification. J Clin Oncol 2006; 24:5552-5564. (Pubitemid 46631336)
3. Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl 2008; 218:154-165.
4. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract a 30-year experience in 252 patients. Urology 1998; 52:594-601. (Pubitemid 28440164)
5. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182:311-322. (Pubitemid 30054364)
6. Sanchez-Carbayo M, Socci ND, Richstone L et al. Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression. Am J Pathol 2007; 171:1650-1658. (Pubitemid 350158325)
7. Wolff EM, Liang G, Jones PA. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005; 2:502-510. (Pubitemid 41594404)
8. Levine AJ. The p53 tumor-suppressor gene. N Engl J Med 1992;326:1350-1352.
9. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (Eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, 2004, pp 90-109.
10. Rosai EJ (Ed): Rosai and Ackerman's Surgical Pathology (9th Edn). Elsevier, China, 2004, pp 1317-1359.
11. Ioachim E, Michael MC, Salmas M et al. Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer 2006; 6:140-147.
12. Larsson P, Wijkstrom H, Thorstenson A et al. A population based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 2003; 37:195-201. (Pubitemid 36791815)
13. Montironi R, Mazzucchelli R, Colanzi P et al. Improving interobserver agreement and certainty level in diagnosing and grading papillary urothelial neoplasms. Usefulness of a Bayesian belief network. Eur Urol 2002; 41:449-457. (Pubitemid 35333943)
14. Reuter VE. Bladder: risk and prognostic factors. A pathologist's perspective. Urol Clin North Am 1999; 26:481-492. (Pubitemid 29411680)
15. Sauter G, Algaba F, Amin MB et al. C. Noninvasive urothelial neoplasias. In: Eble JN, Epstein JI, Sesterhenn I (Eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. IARCC Press, Lyon, 2004, pp 110-123.
16. Shariat SE, Kim J, Raptidis G, Ayala G, Lerner S. Association of p63 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003; 61:1140-1145. (Pubitemid 36693989)
17. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331:1259-1264. (Pubitemid 24333190)
18. Friedrich MG, Riethdorf S, Erbersdobler A. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. Eur Urol 2001; 39:159-166. (Pubitemid 32171182)
19. Tuna B, Yorukoglu K, Tuzel E, Guray M, Mungan U, Kirkali Z. Expression of p53 and mdm-2 and their significance in recurrence of superficial bladder cancer. Pathol Res Pract 2003; 199:323-328. (Pubitemid 36939583)
20. Malicic E, Jankovic R, Jakovljevic K, Radulovic S. TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas. J BUON 2011;16:701-707.
21. Tsiambas E, Kravaritis C, Tsounis D et al. Correlation between different p53 expression patterns and chromosome 17 imbalances in pancreatic ductal carcinoma based on tissue microarray analysis. J BUON 2010;15:94-100.
22. Kilicli-Camur N, Kilicaslan I, Gulluoglu MG, Esen T, Uysal V. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int 2002; 52: 463-469. (Pubitemid 34989304)
23. Gontero P, Casetta G, Zitella A et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000;38:287-296. (Pubitemid 30665955)
24. Rodriguez Alonso A, Pita Fernandez S, Gonzalez-Carrero J, Nogueira March JL. Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67. Acta Urol Esp 2003;27:132-141. (Pubitemid 36389338)
25. Vatne V, Maartmann-Moe H, Hoestmark J. The prognostic value of p53 in superficially infiltrating transitional cell carcinoma. Scand J Urol Nephrol 1995;29:491-495. (Pubitemid 26015163)
26. Vatne V, Maartmann-Moe H, Hoestmark J. Flow cytometric DNA and p53 analysis in superficially infiltrating bladder carcinoma. Anticancer Res 1994; 14:2735-2738.
27. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67- MIB1). Eur Urol 2004;45:606-612. (Pubitemid 38481688)
28. Irie A, Uchida T, Ishida H, Matsumoto K, Iwamura M, Baba S. p53 mutation in bladder cancer patients in Japan and inhibition of growth by in vitro adenovirus-mediated wild-type p53 transduction in bladder cancer cells. Mol Urol 2001;5:53-58. (Pubitemid 32448696)
29. Gönül II, Akyürek N, Dursun A, Küpeli B. Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. Pathol Res Pract 2008; 204:707-717.
30. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Clinical significance and comparison with other prognostic factors. Cancer 2000; 88: 2598-2605. (Pubitemid 30331969)
31. Yurakh AO, Ramos D, Calabuig-Farinas S et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 2006; 50:506-515. (Pubitemid 44189058)
32. Mhawech P, Greloz V, Oppikofer C, Szalay-Quinodoz I, Herrmann F. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer 2004; 100:2367-2374.